Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects-Reference-Cited by-同舟云学术

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

Published:2014-09 Issue:39 Volume:32 Page:5027-5034
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Frey Sharon E.,Reyes Mari Rose Aplasca-De Los,Reynales Humberto,Bermal Nancy Nazaire,Nicolay Uwe,Narasimhan Vas,Forleo-Neto Eduardo,Arora Ashwani Kumar

Funder

Novartis Vaccines and Diagnostics

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference39 articles.

1. CDC influenza update for geriatricians and other clinicians caring for people 65 and older. 2012–2013 influenza season;CDC,2012

2. Antibody response to influenza vaccination in the elderly: a quantitative review;Goodwin;Vaccine,2006

3. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review;Jefferson;Lancet,2005

4. The history of MF59® adjuvant: a phoenix that arose from the ashes;O’Hagan;Expert Rev Vaccines,2013

5. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?;O’Hagan;Clin Pharmacol Ther,2007

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disruptors of sestrin-MAPK interactions rejuvenate T cells and expand TCR specificity;2024-05-21

2. Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis;BMJ Evidence-Based Medicine;2024-04-10

3. Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season;Influenza and Other Respiratory Viruses;2024-04

4. Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials;Influenza and Other Respiratory Viruses;2024-04

5. Vaccine adjuvants and carriers;Advanced Vaccination Technologies for Infectious and Chronic Diseases;2024